Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patients

Trial Profile

Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms AQUARiUS
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 12 Sep 2017 Initial results from AQUARIOUS trial presented at the 42nd European Society for Medical Oncology Congress
    • 29 Jun 2017 Planned End Date changed from 28 Feb 2018 to 21 Mar 2018.
    • 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top